Green K
Department of Ophthalmology, Medical College of Georgia, Augusta, USA.
Arch Ophthalmol. 1998 Nov;116(11):1433-7. doi: 10.1001/archopht.116.11.1433.
To discuss the clinical effects, including toxicological data, of marijuana and its many constituent compounds on the eye and the remainder of the body. A perspective is given on the use of marijuana and the cannabinoids in the treatment of glaucoma.
Although it is undisputed that smoking of marijuana plant material causes a fall in intraocular pressure (IOP) in 60% to 65% of users, continued use at a rate needed to control glaucomatous IOP would lead to substantial systemic toxic effects revealed as pathological changes.
Development of drugs based on the cannabinoid molecule or its agonists for use as topical or oral antiglaucoma medications seems to be worthy of further pursuit. Among the latter chemicals, some have no known adverse psychoactive side effects. Smoking of marijuana plant material for the reduction of elevated IOP in glaucoma is ill-advised, given its toxicological profile.
探讨大麻及其多种成分对眼睛和身体其他部位的临床影响，包括毒理学数据。对大麻和大麻素在青光眼治疗中的应用给出了一种观点。
尽管无可争议的是，吸食大麻植物材料会使60%至65%的使用者眼压下降，但以控制青光眼眼压所需的频率持续使用会导致明显的全身毒性作用，表现为病理变化。
开发基于大麻素分子或其激动剂的药物用作局部或口服抗青光眼药物似乎值得进一步探索。在这些化学物质中，有些尚无已知的不良精神活性副作用。鉴于其毒理学特征，不建议吸食大麻植物材料来降低青光眼患者升高的眼压。
